

By reason of the imminent launch of Ximluci® in Europe, Xbrane Biopharma AB invites to a Capital Markets Day on September 22, 2022

Stockholm, Sweden – Xbrane Biopharma AB (publ) (Nasdaq Stockholm: XBRANE), invites analysts, investors and the media to its Capital Markets Day on September 22, 2022 by reason of EMA's positive opinion for ranibizumab biosimilar candidate Ximluci® (Xlucane®) and the now imminent launch in Europe.

The Capital Markets Day will be held in the Nils Ringertz hall, Biomedicum, floor 3, Solnavägen 9, Solna, starting at 2 pm and will also be broadcast digitally. Refreshments are served from 1.30 pm.

Please register your personal participation at: IR@xbrane.com and digital participation by following the link: <https://tv.streamfabriken.com/xbrane-biopharma-cmd-2022>.

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting SEK 332 billion in annual sales of the respective reference products, with the leading one under registration in Europe. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Attachments

[By reason of the imminent launch of Ximluci® in Europe, Xbrane Biopharma AB invites to a Capital Markets Day on September 22, 2022](#)